Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction - Trial NCT06364150
Access comprehensive clinical trial information for NCT06364150 through Pure Global AI's free database. This Phase 3 trial is sponsored by Seoul National Hospital and is currently Not yet recruiting. The study focuses on Acute Myocardial Infarction. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Seoul National Hospital
Timeline & Enrollment
Phase 3
May 01, 2024
Aug 01, 2026
Primary Outcome
Left ventricular systolic function
Summary
This study will evaluate the efficacy and safety of Therapeutic Use of Autologous-Primed
 Autologous Peripheral Blood Stem Cell Treatment for Myocardial Regeneration in Acute
 Myocardial Infarction.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06364150
Non-Device Trial